Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02018315

Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)

Glucose Transporter Type 1 Deficiency Syndrome Clinical Trial

Official title:
Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)

Clinical Trial Summary

The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain.

The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe and potentially promising by supplying anaplerotic precursors through metabolism of odd-carbon fatty acids that can enter the citric acid cycle (CAC) through alternative metabolic pathways.

Clinical Trial Description

Triheptanoin, a nutritional supplement long used in other metabolic disorders and also added to foods and cosmetics, will be used to complement any diet that G1D patients may be receiving at enrollment with the exception of the ketogenic diet. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02018315
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Completed
Phase Phase 1
Start date January 2012
Completion date March 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02599961 - Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05085704 - Brain Metabolism Observed at 7 Tesla
Withdrawn NCT03202108 - Evaluation of Krio in Children and Adults With Epilepsy N/A
Active, not recruiting NCT04137692 - Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome N/A
Completed NCT03041363 - Treatment Development of Triheptanoin (G1D) Phase 1
Completed NCT04399954 - Evaluation of Ketoflo N/A
Withdrawn NCT02021526 - Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) Phase 1/Phase 2
Recruiting NCT02013583 - The Glucose Transporter Type I Deficiency (G1D) Registry
Completed NCT02915211 - Evaluation of Keyo in Children With Epilepsy N/A
Active, not recruiting NCT02000960 - Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome Phase 2
Active, not recruiting NCT03181399 - Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) Phase 2
No longer available NCT02018302 - Post Study Continuation of C7 for G1D